129 related articles for article (PubMed ID: 38499255)
1. Lipid nanoparticles for local delivery of mRNA to the respiratory tract: Effect of PEG-lipid content and administration route.
Ongun M; Lokras AG; Baghel S; Shi Z; Schmidt ST; Franzyk H; Rades T; Sebastiani F; Thakur A; Foged C
Eur J Pharm Biopharm; 2024 May; 198():114266. PubMed ID: 38499255
[TBL] [Abstract][Full Text] [Related]
2. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
[TBL] [Abstract][Full Text] [Related]
3. Engineering Lipid Nanoparticles for Enhanced Intracellular Delivery of mRNA through Inhalation.
Kim J; Jozic A; Lin Y; Eygeris Y; Bloom E; Tan X; Acosta C; MacDonald KD; Welsher KD; Sahay G
ACS Nano; 2022 Sep; 16(9):14792-14806. PubMed ID: 36038136
[TBL] [Abstract][Full Text] [Related]
4. Visible Light Conjugation with Triazolinediones as a Route to Degradable Poly(ethylene glycol)-Lipids for mRNA Lipid Nanoparticle Formulation.
Golba B; Soete M; Zhong Z; Sanders N; Du Prez FE; Houck HA; De Geest BG
Angew Chem Int Ed Engl; 2023 Jun; 62(23):e202301102. PubMed ID: 36896730
[TBL] [Abstract][Full Text] [Related]
5. Influence of lipid composition of messenger RNA-loaded lipid nanoparticles on the protein expression via intratracheal administration in mice.
Geng L; Kato N; Kodama Y; Mukai H; Kawakami S
Int J Pharm; 2023 Apr; 637():122896. PubMed ID: 36972778
[TBL] [Abstract][Full Text] [Related]
6. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs.
Lokugamage MP; Vanover D; Beyersdorf J; Hatit MZC; Rotolo L; Echeverri ES; Peck HE; Ni H; Yoon JK; Kim Y; Santangelo PJ; Dahlman JE
Nat Biomed Eng; 2021 Sep; 5(9):1059-1068. PubMed ID: 34616046
[TBL] [Abstract][Full Text] [Related]
7. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery.
Zimmermann CM; Baldassi D; Chan K; Adams NBP; Neumann A; Porras-Gonzalez DL; Wei X; Kneidinger N; Stoleriu MG; Burgstaller G; Witzigmann D; Luciani P; Merkel OM
J Control Release; 2022 Nov; 351():137-150. PubMed ID: 36126785
[TBL] [Abstract][Full Text] [Related]
8. Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury.
Waggoner LE; Miyasaki KF; Kwon EJ
Biomater Sci; 2023 Jun; 11(12):4238-4253. PubMed ID: 36987922
[TBL] [Abstract][Full Text] [Related]
9. Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA.
Miao H; Huang K; Li Y; Li R; Zhou X; Shi J; Tong Z; Sun Z; Yu A
Int J Pharm; 2023 Jun; 640():123050. PubMed ID: 37201764
[TBL] [Abstract][Full Text] [Related]
10. Lipid nanoparticles containing labile PEG-lipids transfect primary human skin cells more efficiently in the presence of apoE.
Gregersen CH; Mearraoui R; Søgaard PP; Clergeaud G; Petersson K; Urquhart AJ; Simonsen JB
Eur J Pharm Biopharm; 2024 Apr; 197():114219. PubMed ID: 38368913
[TBL] [Abstract][Full Text] [Related]
11. Microfluidic Platform Enables Shearless Aerosolization of Lipid Nanoparticles for mRNA Inhalation.
Kim J; Jozić A; Bloom E; Jones B; Marra M; Murthy NTV; Eygeris Y; Sahay G
ACS Nano; 2024 Apr; 18(17):11335-11348. PubMed ID: 38621181
[TBL] [Abstract][Full Text] [Related]
12. Tailored Monoacyl Poly(2-oxazoline)- and Poly(2-oxazine)-Lipids as PEG-Lipid Alternatives for Stabilization and Delivery of mRNA-Lipid Nanoparticles.
He X; Payne TJ; Takanashi A; Fang Y; Kerai SD; Morrow JP; Al-Wassiti H; Pouton CW; Kempe K
Biomacromolecules; 2024 Jun; ():. PubMed ID: 38918933
[TBL] [Abstract][Full Text] [Related]
13. Lipid nanoparticle-based mRNA candidates elicit potent T cell responses.
Zeng Y; Escalona-Rayo O; Knol R; Kros A; Slütter B
Biomater Sci; 2023 Jan; 11(3):964-974. PubMed ID: 36537916
[TBL] [Abstract][Full Text] [Related]
14. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
15. Aerosolizable Lipid Nanoparticles for Pulmonary Delivery of mRNA through Design of Experiments.
Zhang H; Leal J; Soto MR; Smyth HDC; Ghosh D
Pharmaceutics; 2020 Oct; 12(11):. PubMed ID: 33143328
[TBL] [Abstract][Full Text] [Related]
16. Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery.
Swingle KL; Billingsley MM; Bose SK; White B; Palanki R; Dave A; Patel SK; Gong N; Hamilton AG; Alameh MG; Weissman D; Peranteau WH; Mitchell MJ
J Control Release; 2022 Jan; 341():616-633. PubMed ID: 34742747
[TBL] [Abstract][Full Text] [Related]
17. Elucidation of lipid nanoparticle surface structure in mRNA vaccines.
Wang MM; Wappelhorst CN; Jensen EL; Chi YT; Rouse JC; Zou Q
Sci Rep; 2023 Oct; 13(1):16744. PubMed ID: 37798336
[TBL] [Abstract][Full Text] [Related]
18. Inhalable dry powder product (DPP) of mRNA lipid nanoparticles (LNPs) for pulmonary delivery.
Sarode A; Patel P; Vargas-Montoya N; Allawzi A; Zhilin-Roth A; Karmakar S; Boeglin L; Deng H; Karve S; DeRosa F
Drug Deliv Transl Res; 2024 Feb; 14(2):360-372. PubMed ID: 37526881
[TBL] [Abstract][Full Text] [Related]
19. PEG-OligoRNA Hybridization of mRNA for Developing Sterically Stable Lipid Nanoparticles toward In Vivo Administration.
Kurimoto S; Yoshinaga N; Igarashi K; Matsumoto Y; Cabral H; Uchida S
Molecules; 2019 Apr; 24(7):. PubMed ID: 30987102
[TBL] [Abstract][Full Text] [Related]
20. Naturally Derived Membrane Lipids Impact Nanoparticle-Based Messenger RNA Delivery.
Kim J; Jozic A; Sahay G
Cell Mol Bioeng; 2020 Oct; 13(5):463-474. PubMed ID: 32837581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
